COVID-19 subphenotypes at hospital admission are associated with mortality: a cross-sectional study

References

• Bilinski A, Emanuel EJ. COVID-19 and excess all-cause mortality in the US and 18 comparison countries. JAMA. 2020;324(20):2100–2102.
   PubMed Web of Science ®Google Scholar
• Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689–697.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention [CDC]. Estimated Disease Burden of COVID-19. 2020; [cited 2021 April 20]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html
   Google Scholar
• Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. J Community Health. 2020;45(6):1270–1282.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Carrasco-Sánchez FJ, López-Carmona MD, Martínez-Marcos FJ, et al. Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 registry. Ann Med. 2021;53(1):103–116.
   PubMed Web of Science ®Google Scholar
• Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770.
   PubMed Web of Science ®Google Scholar
• Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11.
   PubMed Web of Science ®Google Scholar
• Wang X, Jehi L, Ji X, et al. Phenotypes and subphenotypes of patients with coronavirus disease 2019: a latent class modeling analysis. Chest. 2021;159(6):2191–2204.
   PubMed Web of Science ®Google Scholar
• Legrand M, Phillips RV, Malenica I, et al. Differences in clinical deterioration among three sub-phenotypes of COVID-19 patients at the time of first positive test: results from a clustering analysis. Intensive Care Med. 2021;47(1):113–115.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–725.
   PubMed Web of Science ®Google Scholar
• Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611–620.
   PubMed Web of Science ®Google Scholar
• Sinha P, Furfaro D, Cummings MJ, et al. Latent class analysis reveals COVID-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids. Am J Respir Crit Care Med. 2021;204(11):1274–1285.
   PubMed Web of Science ®Google Scholar
• Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6(9):691–698.
   PubMed Web of Science ®Google Scholar
• Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195(3):331–338.
   PubMed Web of Science ®Google Scholar
• Sinha P, Delucchi KL, Thompson BT, et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 2018;44(11):1859–1869.
   PubMed Web of Science ®Google Scholar
• Xie J, Hungerford D, Chen H, et al. Development and external validation of a prognostic multivariable model on admission for hospitalized patients with COVID-19. 2020. medRxiv.
   Google Scholar
• Vaid A, Somani S, Russak AJ, et al. Machine learning to predict mortality and critical events in a cohort of patients with COVID-19 in New York city: model development and validation. J Med Internet Res. 2020;22(11):e24018.
   PubMed Web of Science ®Google Scholar
• Ma X, Ng M, Xu S, et al. Development and validation of prognosis model of mortality risk in patients with COVID-19. Epidemiol Infect. 2020;148:e168–e168.
   Web of Science ®Google Scholar
• Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with Covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ. 2020;370:m3339.
   PubMed Web of Science ®Google Scholar
• Zhang S, Guo M, Duan L, et al. Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. Crit Care. 2020;24(1):438.
   PubMed Web of Science ®Google Scholar
• Su C, Zhang Y, Flory JH, et al. Clinical subphenotypes in COVID-19: derivation, validation, prediction, temporal patterns, and interaction with social determinants of health. NPJ Digit Med. 2021;4(1):110.
   PubMed Web of Science ®Google Scholar
• Ranard BL, Megjhani M, Terilli K, et al. Identification of endotypes of hospitalized COVID-19 patients. Front Med. 2021;8:770343.
   Web of Science ®Google Scholar
• Vasquez CR, Gupta S, Miano TA, et al. Identification of distinct clinical subphenotypes in critically ill patients with COVID-19. Chest. 2021;160(3):929–943.
   PubMed Web of Science ®Google Scholar
• Su C, Xu Z, Hoffman K, et al. Identifying organ dysfunction trajectory-based subphenotypes in critically ill patients with COVID-19. Sci Rep. 2021;11(1):15872.
   PubMed Web of Science ®Google Scholar
• Prescott HC, Calfee CS, Thompson BT, et al. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med. 2016;194(2):147–155.
   PubMed Web of Science ®Google Scholar
• Maley JH, Thompson BT. Embracing the heterogeneity of ARDS. Chest. 2019;155(3):453–455.
   PubMed Web of Science ®Google Scholar
• Amati F, Dela Cruz CS. One size does not fit all: moving towards a personalized approach for steroids in COVID-19. Chest. 2021;159(5):1693–1695.
   PubMed Web of Science ®Google Scholar
• Hajifathalian K, Sharaiha RZ, Kumar S, et al. Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: a proposal for the COVID-AID risk tool. PLoS One. 2020;15(9):e0239536.
   PubMed Web of Science ®Google Scholar
• Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
   PubMed Web of Science ®Google Scholar
• Chen W, Qian L, Shi J, et al. Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification. BMC Med Res Methodol. 2018;18(1):63.
   PubMedGoogle Scholar
• Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–706.
   PubMed Web of Science ®Google Scholar
• Zeileis A, Köll S, Graham N. Various versatile variances: an object-oriented implementation of clustered covariances in R. J Stat Soft. 2020;95(1):1–36.
   Web of Science ®Google Scholar
• Zeileis A. Object-oriented computation of sandwich estimators. J Stat Soft. 2006;16(9):1–16.
   Web of Science ®Google Scholar
• Linzer DA, Lewis JB. poLCA: an R package for polytomous variable latent class analysis. J Stat Soft. 2011;42(10):1–29.
   Web of Science ®Google Scholar
• Linzer D Jeffrey. poLCA: polytomous Variable Latent Class Analysis. 2013. R package version 1.4.
   Google Scholar
• Lusczek ER, Ingraham NE, Karam BS, et al. Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles. PLoS One. 2021;16(3):e0248956.
   PubMed Web of Science ®Google Scholar
• Chen H, Xie J, Su N, et al. Corticosteroid therapy is associated with improved outcome in critically ill patients with COVID-19 with hyperinflammatory phenotype. Chest. 2021;159(5):1793–1802.
   PubMed Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–1643.
   PubMed Web of Science ®Google Scholar
• Hariyanto TI, Japar KV, Kwenandar F, et al. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis. Am J Emerg Med. 2021;41:110–119.
   PubMed Web of Science ®Google Scholar
• Wu J, Song S, Cao H-C, et al. Liver diseases in COVID-19: etiology, treatment and prognosis. World J Gastroenterol. 2020;26(19):2286–2293.
   PubMed Web of Science ®Google Scholar
• Heilmann E, Gregoriano C, Wirz Y, et al. Association of kidney function with effectiveness of procalcitonin-guided antibiotic treatment: a patient-level meta-analysis from randomized controlled trials. Clin Chem Lab Med. 2021;59(2):441–453.
   Web of Science ®Google Scholar
• Mariette X, Hermine O, Tharaux P-L, et al. Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial. JAMA Intern Med. 2021;181(9):1241.
   PubMed Web of Science ®Google Scholar
• Interleukin-6 receptor antagonists in critically ill patients with covid-19. New Eng J Med. 2021;385:1147–1149.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503–1516.
   PubMed Web of Science ®Google Scholar
• Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24–31.
   PubMed Web of Science ®Google Scholar
• Hermine O, Mariette X, Tharaux P-L, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32–40.
   PubMed Web of Science ®Google Scholar
• Group, T.W.R.E.A.f.C.-T.W. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326(6):499–518.
   PubMed Web of Science ®Google Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619–629.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Mukherjee A, Kumar G, PLACID Trial Collaborators, et al. Convalescent plasma in the management of moderate Covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020;371:m3939.
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from covid-19. N Engl J Med. 2021;384(11):1015–1027.
   PubMed Web of Science ®Google Scholar
• Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe covid-19 in older adults. N Engl J Med. 2021;384(7):610–618.
   PubMed Web of Science ®Google Scholar
• Horby PW, Estcourt L, Peto L, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv; 2021. p. 2021.03.09.21252736.
   Google Scholar
• Su C, Xu Z, Hoffman K, et al. Identifying organ dysfunction trajectory-based subphenotypes in critically ill patients with COVID-19. medRxiv; 2020. p. 2020.07.16.20155382.
   Google Scholar
• Delucchi K, Famous KR, Ware LB, et al. Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax. 2018;73(5):439–445.
   PubMed Web of Science ®Google Scholar